Results 121 to 130 of about 476,894 (337)

Ageism in Rheumatology: The Health Care Professional's Perspective

Arthritis Care &Research, EarlyView.
Objective Ageism (age‐based stereotypes, prejudice, or discrimination) is prevalent and linked to prolonged disability and reduced lifespan in older adults. Little is known about ageism within rheumatology. This study explores the health care professional's (HCP) perception of the care of older adults and how ageist attitudes or perspectives may impact
Aaron P. Smith, Pooja M. Achanta, Jiha Lee, Namrata Singh, Una E. Makris   +4 more
wiley   +1 more source

Text mining for the Vaccine Adverse Event Reporting System: medical text classification using informative feature selection [PDF]

, 2011
Taxiarchis Botsis, Michael Nguyen, Emily Jane Woo, Marianthi Markatou, Robert Ball   +4 more
openalex   +1 more source

Under-reporting of Adverse Drug Reactions to the Food & Drug Administration [PDF]

, 2018
This study examined the potential significant differences in the distribution of adverse drug reactions (ADRs) by reporter (consumer versus physician) and patient outcome at case and event level. This study also contains exploratory questions to evaluate
Lamb, James Alexander
core   +1 more source

Association Between Sleep Disturbance and Subsequent Pain Interference in Patients With Early Rheumatoid Arthritis

Arthritis Care &Research, EarlyView.
Objective This study investigated whether sleep disturbance can predict the extent to which pain interferes with daily functioning in patients with early rheumatoid arthritis (RA). Methods Data were from adults with early RA (joint symptoms ≤12 months) enrolled in the Canadian Early Arthritis Cohort between 2016 and 2023.
Burcu Aydemir, Orit Schieir, Marie‐France Valois, Lutfiyya N. Muhammad, Jing Song, Dorothy Dunlop, Rowland W. Chang, Susan J. Bartlett, Louis Bessette, Gilles Boire, Glen Hazlewood, Carol Hitchon, Janet Pope, Carter Thorne, Diane Tin, Vivian P. Bykerk, Yvonne C. Lee   +16 more
wiley   +1 more source

Assessing the safety of bedaquiline: insight from adverse event reporting system analysis

Frontiers in Pharmacology
BackgroundThe development and marketing of Bedaquiline (BDQ) represent significant advancements in treating tuberculosis, particularly multidrug-resistant forms.
Jiaqiang Wu, Hong Pan, Li Shen, Mingyi Zhao   +3 more
doaj   +1 more source

Adverse Event Profiles of Platinum Agents: Data Mining of the Public Version of the FDA Adverse Event Reporting System, AERS, and Reproducibility of Clinical Observations [PDF]

, 2011
Toshiyuki Sakaeda, Kaori Kadoyama, Yasushi Okuno   +2 more
openalex   +1 more source

Analysis of postmarketing neuropsychiatric adverse events of avapritinib based on the FDA adverse event reporting system

Scientific Reports
Neuropsychiatric adverse events (AEs) significantly impact the quality of life of patients using avapritinib. However, the majority of current data comes from pre-marketing, with limited real-world studies. Our research aimed to explore post-marketing data of avapritinib.
Wei Mao, Junyan Jiang, Yanping Xia, Lin Zhang   +3 more
openaire   +3 more sources

Where, how, and how much? A multicenter cohort study of the relationship between lupus decision aid modality, place of administration, interruption and viewing completeness and patient‐reported outcomes

Arthritis Care &Research, Accepted Article.
Objective We assessed whether shared decision‐making (SDM), and patient acceptability, feasibility, and overall satisfaction with a computerized patient decision aid (PtDA) for patients with systemic lupus erythematosus (SLE), differs by PtDA setting, modality, and the viewing experience.
Jasvinder A. Singh, Mark Beasley, Larry R. Hearld, for the Implementing DEcision‐Aid for Lupus in clinics (IDEAL) Consortium   +3 more
wiley   +1 more source

Alpelisib-related adverse events: The FDA Adverse Event Reporting System Database (FAERS) pharmacovigilance study

Heliyon
Background: Alpelisib was approved for treatment of breast cancer. We assessed the safety signals associated with alpelisib by data mining the FDA pharmacovigilance database. Methods: Data from the second quarter of 2019 to the fourth quarter of 2022 had
Yun Li, Hang Li, Zhongyuan Xiang
doaj  

Platinum Agent-Induced Hypersensitivity Reactions: Data Mining of the Public Version of the FDA Adverse Event Reporting System, AERS [PDF]

, 2011
Toshiyuki Sakaeda, Kaori Kadoyama, Hiroaki Yabuuchi, Satoshi Niijima, Kyoko Seki, Yukinari Shiraishi, Yasushi Okuno   +6 more
openalex   +1 more source